Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinic…
Biotechnology
US, San Diego [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 28.92 | 7.54 | 5.85 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 184.90 | 1.21 | 0.43 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Book Value | 16.33 | 14.56 | 12.52 | |
| Cash | 12.24 | 15.02 | 13.38 | |
| Capex | 95.53 | < 0.005 | -0.01 | |
| Free Cash Flow | 2.52 | -2.21 | -2.27 | |
| Revenue | 7.33 | 0.25 | 0.24 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 0.73 | 0.91 | 0.91 | |
| Operating Margin | 23.31 | -10.49 | -13.68 | |
| ROA | 25.87 | -0.14 | -0.19 | |
| ROE | 29.52 | -0.17 | -0.24 | |
| ROIC | 27.63 | -0.16 | -0.23 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of MRTX is permitted for members.
5
Growth
The "Growth Entry" for the Focus of MRTX is permitted for members.
6
Leverage & Liquidity